{"id":"lcp-tacrolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus is a calcineurin inhibitor that prevents dephosphorylation of NFAT, blocking IL-2 and other cytokine production critical for T-cell activation. The lipid conjugation (LCP formulation) enhances lymphoid tissue targeting and oral bioavailability, allowing improved immunosuppression with potentially reduced systemic exposure compared to conventional tacrolimus.","oneSentence":"LCP-tacrolimus is a lipid-conjugated prodrug of tacrolimus that inhibits calcineurin to suppress T-cell activation and proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:40.666Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention"},{"name":"Graft-versus-host disease (GVHD)"}]},"trialDetails":[{"nctId":"NCT06354179","phase":"PHASE4","title":"Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-04-15","conditions":"Liver Transplantation, Immunosuppression","enrollment":162},{"nctId":"NCT06833463","phase":"","title":"Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients","status":"RECRUITING","sponsor":"Chiesi Poland Sp. z o.o.","startDate":"2025-05-29","conditions":"Kidney Transplant","enrollment":120},{"nctId":"NCT04665310","phase":"PHASE4","title":"Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-09-01","conditions":"Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant","enrollment":46},{"nctId":"NCT04469842","phase":"EARLY_PHASE1","title":"Early Use of Long-acting Tacrolimus in Lung Transplant Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-12-01","conditions":"Lung Transplant; Complications","enrollment":48},{"nctId":"NCT04489134","phase":"PHASE2","title":"P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2022-02-15","conditions":"Pharmacokinetics","enrollment":27},{"nctId":"NCT05396898","phase":"PHASE4","title":"Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial)","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2020-12-16","conditions":"Posttransplant Diabetes Mellitus","enrollment":44},{"nctId":"NCT05089604","phase":"PHASE4","title":"Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2023-01-09","conditions":"Liver Transplantation, Immunosuppression, Neurotoxicity","enrollment":124},{"nctId":"NCT04496401","phase":"PHASE4","title":"PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2020-09-28","conditions":"Kidney Transplantation, Pancreas Transplantation, Diabetes","enrollment":25},{"nctId":"NCT05001074","phase":"PHASE3","title":"Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients","status":"UNKNOWN","sponsor":"Heleen Grootjans","startDate":"2020-07-28","conditions":"Lung Transplant; Complications","enrollment":145},{"nctId":"NCT03289650","phase":"PHASE3","title":"Extended Release Tacrolimus vs. Twice-Daily Tacrolimus","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2017-09-05","conditions":"End Stage Renal Disease, Rejection of Renal Transplant","enrollment":29},{"nctId":"NCT02961608","phase":"PHASE4","title":"Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day.","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2016-05","conditions":"Kidney Transplant; Complications","enrollment":25},{"nctId":"NCT00608894","phase":"PHASE2","title":"LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis","status":"TERMINATED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-12","conditions":"Autoimmune Hepatitis","enrollment":13},{"nctId":"NCT01962922","phase":"PHASE3","title":"Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2013-11","conditions":"Renal Failure","enrollment":50},{"nctId":"NCT01187953","phase":"PHASE3","title":"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2010-09","conditions":"Renal Failure","enrollment":543},{"nctId":"NCT01438710","phase":"PHASE3","title":"Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2011-12","conditions":"Renal Failure, Tremors","enrollment":44},{"nctId":"NCT00817206","phase":"PHASE3","title":"Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-12","conditions":"Renal Failure","enrollment":326},{"nctId":"NCT00608244","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-11","conditions":"Liver Failure","enrollment":59},{"nctId":"NCT00496483","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-07","conditions":"Renal Failure","enrollment":60},{"nctId":"NCT01666951","phase":"PHASE2","title":"Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2012-11","conditions":"Renal Failure","enrollment":36},{"nctId":"NCT00772148","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-10","conditions":"Liver Failure","enrollment":58},{"nctId":"NCT00765661","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-09","conditions":"Kidney Failure, Renal Failure","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Envarsus®"],"phase":"marketed","status":"active","brandName":"LCP-tacrolimus","genericName":"LCP-tacrolimus","companyName":"University Hospital Tuebingen","companyId":"university-hospital-tuebingen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LCP-tacrolimus is a lipid-conjugated prodrug of tacrolimus that inhibits calcineurin to suppress T-cell activation and proliferation. Used for Organ transplant rejection prevention, Graft-versus-host disease (GVHD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}